Current and Emerging Treatment Options in Diabetes Care

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Standard

Current and Emerging Treatment Options in Diabetes Care. / Clemmensen, Christoffer; Müller, Timo D; Finan, Brian; Tschöp, Matthias H; DiMarchi, Richard.

Metabolic Control. Vol. 233 Springer, 2016. p. 437-459 (Handbook of Experimental Pharmacology; No. 233).

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Harvard

Clemmensen, C, Müller, TD, Finan, B, Tschöp, MH & DiMarchi, R 2016, Current and Emerging Treatment Options in Diabetes Care. in Metabolic Control. vol. 233, Springer, Handbook of Experimental Pharmacology, no. 233, pp. 437-459. https://doi.org/10.1007/164_2015_7

APA

Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. (2016). Current and Emerging Treatment Options in Diabetes Care. In Metabolic Control (Vol. 233, pp. 437-459). Springer. Handbook of Experimental Pharmacology No. 233 https://doi.org/10.1007/164_2015_7

Vancouver

Clemmensen C, Müller TD, Finan B, Tschöp MH, DiMarchi R. Current and Emerging Treatment Options in Diabetes Care. In Metabolic Control. Vol. 233. Springer. 2016. p. 437-459. (Handbook of Experimental Pharmacology; No. 233). https://doi.org/10.1007/164_2015_7

Author

Clemmensen, Christoffer ; Müller, Timo D ; Finan, Brian ; Tschöp, Matthias H ; DiMarchi, Richard. / Current and Emerging Treatment Options in Diabetes Care. Metabolic Control. Vol. 233 Springer, 2016. pp. 437-459 (Handbook of Experimental Pharmacology; No. 233).

Bibtex

@inbook{b70043ba78014d929a29bd7b2deb4fb3,
title = "Current and Emerging Treatment Options in Diabetes Care",
abstract = "Diabetes constitutes an increasing threat to human health, particularly in newly industrialized and densely populated countries. Type 1 and type 2 diabetes arise from different etiologies but lead to similar metabolic derangements constituted by an absolute or relative lack of insulin that results in elevated plasma glucose. In the last three decades, a set of new medicines built upon a deeper understanding of physiology and diabetic pathology have emerged to enhance the clinical management of the disease and related disorders. Recent insights into insulin-dependent and insulin-independent molecular events have accelerated the generation of a series of novel medicinal agents, which hold the promise for further advances in the management of diabetes. In this chapter, we provide a historical context for what has been accomplished to provide perspective for future research and novel emerging treatment options.",
keywords = "Anti-Obesity Agents, Bariatric Surgery, Diabetes Mellitus, Fibroblast Growth Factors, Glucose, Humans, Hypoglycemic Agents, Leptin, Pancreas Transplantation, Journal Article, Review",
author = "Christoffer Clemmensen and M{\"u}ller, {Timo D} and Brian Finan and Tsch{\"o}p, {Matthias H} and Richard DiMarchi",
year = "2016",
doi = "10.1007/164_2015_7",
language = "English",
isbn = "978-3-319-29804-7",
volume = "233",
series = "Handbook of Experimental Pharmacology",
publisher = "Springer",
number = "233",
pages = "437--459",
booktitle = "Metabolic Control",
address = "Switzerland",

}

RIS

TY - CHAP

T1 - Current and Emerging Treatment Options in Diabetes Care

AU - Clemmensen, Christoffer

AU - Müller, Timo D

AU - Finan, Brian

AU - Tschöp, Matthias H

AU - DiMarchi, Richard

PY - 2016

Y1 - 2016

N2 - Diabetes constitutes an increasing threat to human health, particularly in newly industrialized and densely populated countries. Type 1 and type 2 diabetes arise from different etiologies but lead to similar metabolic derangements constituted by an absolute or relative lack of insulin that results in elevated plasma glucose. In the last three decades, a set of new medicines built upon a deeper understanding of physiology and diabetic pathology have emerged to enhance the clinical management of the disease and related disorders. Recent insights into insulin-dependent and insulin-independent molecular events have accelerated the generation of a series of novel medicinal agents, which hold the promise for further advances in the management of diabetes. In this chapter, we provide a historical context for what has been accomplished to provide perspective for future research and novel emerging treatment options.

AB - Diabetes constitutes an increasing threat to human health, particularly in newly industrialized and densely populated countries. Type 1 and type 2 diabetes arise from different etiologies but lead to similar metabolic derangements constituted by an absolute or relative lack of insulin that results in elevated plasma glucose. In the last three decades, a set of new medicines built upon a deeper understanding of physiology and diabetic pathology have emerged to enhance the clinical management of the disease and related disorders. Recent insights into insulin-dependent and insulin-independent molecular events have accelerated the generation of a series of novel medicinal agents, which hold the promise for further advances in the management of diabetes. In this chapter, we provide a historical context for what has been accomplished to provide perspective for future research and novel emerging treatment options.

KW - Anti-Obesity Agents

KW - Bariatric Surgery

KW - Diabetes Mellitus

KW - Fibroblast Growth Factors

KW - Glucose

KW - Humans

KW - Hypoglycemic Agents

KW - Leptin

KW - Pancreas Transplantation

KW - Journal Article

KW - Review

U2 - 10.1007/164_2015_7

DO - 10.1007/164_2015_7

M3 - Book chapter

C2 - 25903416

SN - 978-3-319-29804-7

VL - 233

T3 - Handbook of Experimental Pharmacology

SP - 437

EP - 459

BT - Metabolic Control

PB - Springer

ER -

ID: 199074987